Novo Nordisk increases commitment to stem cell-based therapies

16 May 2018 08:01 CET Bagsværd, Denmark, 16 May 2018 ­- Novo Nordisk today announced an increased commitment to stem cell-based therapies and an expansion of the focus on type 1 diabetes into other serious chronic diseases. This has been made

Novo Nordisk participates in new research project Hypo-RESOLVE to investigate hypoglycaemia and its impact in diabetes

The international consortium aims to provide evidence-based classification of hypoglycaemia to achieve better treatments for people living with diabetes Copenhagen, Denmark, 1 May 2018 – Within the newly started European research project Hypo-RESOLVE, 23 leading international players from academia, industry and

Novo Nordisk A/S – Share repurchase programme

Novo Nordisk A/S – Share repurchase programme Bagsværd, Denmark, 1 May 2018 – On 5 February 2018, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16

Red Cross and Novo Nordisk announce ground-breaking partnership to tackle chronic care in humanitarian crises

Many more people are today affected by chronic non-communicable diseases (NCDs) than by communicable diseases. This is not reflected in resources for health in general and much less in humanitarian crises.  Copenhagen, Denmark, 18 April 2018 – The International Committee of

Novo Nordisk obtains exclusive worldwide licence to EpiDestiny’s sickle cell disease programme

Bagsværd, Denmark, 5 April 2018 ­– Novo Nordisk and EpiDestiny today announced that Novo Nordisk has obtained an exclusive worldwide licence to EpiDestiny’s sickle cell disease (SCD) programme, EPI01. EpiDestiny is eligible to receive more than 400 million US dollars